Literature DB >> 11260863

Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.

C He1, P He, L P Liu, Y S Zhu.   

Abstract

PURPOSE: To determine the expressive patterns of the components of the plasminogen activator system in human large-cell lung carcinoma strains and to analyze the effects of the patterns on tumor invasion and metastasis.
METHODS: The in vitro and in vivo invasive and metastatic potential of two human large-cell lung carcinoma strains with high (strain 95D) and low (strain 95C) metastatic potential was further confirmed by the Boyden chamber model and nude mice model. After this, the expressions of the components of the plasminogen activator system--including urokinase-type and tissue-type plasminogen activator (uPA and tPA), urokinase receptor (uPAR), and type-1 and type-2 plasminogen activator inhibitor (PAI-1 and PAI-2) in strain 95D and 95C cells--were determined by RT-PCR and immunohistochemical staining. The effects of monoclonal antibodies of uPA, uPAR, and PAI-1 on the invasive potential of strain 95D cell line were also evaluated.
RESULTS: Strain 95D cells were found to have a stronger in vitro and in vivo invasive and metastatic potential than strain 95C cells. In the former, the average number of infiltrating cells in the in vitro model in one field of vision (40055) was 73.75 +/- 7.42, while in the latter, it was 56.33 +/- 6.28 (P < 0.001). Lung metastatic loci were observed in all six nude mice inoculated with 95D cells (6/6), but not in any of the nude mice inoculated with 95C cells (0/6). The high-metastatic strain 95D cells expressed higher uPA and uPAR and lower tPA and PAI-2 than the low-metastatic strain 95C cells. The PAI-1 expressions in both 95D and 95C cells were almost the same. Monoclonal antibodies of uPA and uPAR greatly reduced the invasive potential of strain 95D cells in vitro.
CONCLUSIONS: These data suggest that the invasive and metastatic potential of human large-cell lung carcinoma cell lines is associated with differential expressions of the components of the plasminogen activator system and that the determination of these components may be used as a marker for judging clinically the possibility of tumor metastasis as well as the prognoses of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260863     DOI: 10.1007/s004320000192

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.

Authors:  Crispin R Dass; Anne P W Nadesapillai; Daniel Robin; Monique L Howard; Jane L Fisher; Hong Zhou; Peter F M Choong
Journal:  Clin Exp Metastasis       Date:  2006-04-29       Impact factor: 5.150

2.  Cancer Cell Derived Small Extracellular Vesicles Contribute to Recipient Cell Metastasis Through Promoting HGF/c-Met Pathway.

Authors:  Zhi Qiao; Yan Zhang; Maolin Ge; Sha Liu; Xiaoteng Jiang; Zhi Shang; Han Liu; Chengxi Cao; Hua Xiao
Journal:  Mol Cell Proteomics       Date:  2019-06-13       Impact factor: 5.911

3.  A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.

Authors:  Xia Wang; Min Hou; Li Tan; Xinghui Sun; Yuqing Zhang; Ping Li; Yunsong Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-12       Impact factor: 4.553

4.  Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.

Authors:  Chi-Hui Tang; Marla L Hill; Alexis N Brumwell; Harold A Chapman; Ying Wei
Journal:  J Cell Sci       Date:  2008-10-21       Impact factor: 5.285

5.  CCR1 knockdown suppresses human non-small cell lung cancer cell invasion.

Authors:  Chang-Li Wang; Bing-Sheng Sun; Yong Tang; Hong-Qing Zhuang; Wei-Zhi Cao
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-30       Impact factor: 4.553

6.  Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.

Authors:  C Ostheimer; C Evers; M Bache; T Reese; D Vordermark
Journal:  Strahlenther Onkol       Date:  2018-01-16       Impact factor: 3.621

7.  Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases.

Authors:  Manfred Volm; Reet Koomägi; Jürgen Mattern; Thomas Efferth
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

8.  Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.

Authors:  Song Yi Bae; Hyen Joo Park; Ji-Young Hong; Hye-Jung Lee; Sang Kook Lee
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

9.  miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2).

Authors:  Heyong Wang; Yingchao Zhu; Mingchuan Zhao; Chunlian Wu; Peng Zhang; Liang Tang; Huijun Zhang; Xiaofeng Chen; Yaoqin Yang; Gentao Liu
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

10.  Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

Authors:  Xiang Xu; Yuan Cai; Ying Wei; Fernando Donate; Jose Juarez; Graham Parry; Liqing Chen; Edward J Meehan; Richard W Ahn; Andrey Ugolkov; Oleksii Dubrovskyi; Thomas V O'Halloran; Mingdong Huang; Andrew P Mazar
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.